Skip to main
MRUS

Merus (MRUS) Stock Forecast & Price Target

Merus (MRUS) Analyst Ratings

Based on 15 analyst ratings
Hold
Strong Buy 13%
Buy 13%
Hold 73%
Sell 0%
Strong Sell 0%

Bulls say

Merus NV is positioned favorably following Genmab's announced acquisition offer at $97 per share, representing a 41% premium and valuing the company at approximately $8 billion. The acquisition enhances Genmab’s late-stage pipeline and aligns with its strategy for long-term growth, particularly with the promising asset petosemtamab, which is in Phase 3 development and expected to generate significant revenue as early as 2029. Additionally, Merus' involvement in developing bispecific antibody therapeutics remains a key strength, underscoring the strategic value and market potential inherent in the company's innovative product pipeline.

Bears say

Merus NV's stock outlook has been downgraded to Neutral due to the impending acquisition by Genmab, with a significant reduction in the price target from $135 to $97, reflecting an all-cash transaction valued at approximately $8 billion. The downgrade is compounded by concerns over the financing structure of the acquisition, as Genmab plans to utilize a combination of cash reserves and $5.5 billion in non-convertible debt, raising questions about the potential impact on Merus's financial stability and future growth prospects. Additionally, the expectation that no higher bids are likely to emerge further diminishes potential value appreciation for Merus's shareholders in the near term.

Merus (MRUS) has been analyzed by 15 analysts, with a consensus rating of Hold. 13% of analysts recommend a Strong Buy, 13% recommend Buy, 73% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merus (MRUS) Forecast

Analysts have given Merus (MRUS) a Hold based on their latest research and market trends.

According to 15 analysts, Merus (MRUS) has a Hold consensus rating as of Dec 31, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $94.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $94.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merus (MRUS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.